Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Colin Wernsdörfer"'
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 16, Iss 7, Pp 15271-15286 (2015)
Volume 16
Issue 7
Pages 15271-15286
International Journal of Molecular Sciences, Vol 16, Iss 7, Pp 15271-15286 (2015)
Volume 16
Issue 7
Pages 15271-15286
The efficacy and safety of first-line disease-modifying therapies (DMT) for relapsing-remitting multiple sclerosis (RRMS) has been demonstrated in pivotal, randomized trials, but these studies do not reflect the routine care setting where treatment g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0badc05454bb86cfe67e95b6eaf6d1c
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-148487
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-148487
Autor:
Joerg Hasford, Gabriele Kalski, Peter Haller, Andrea Viehöver, Jürgen Koehler, Colin Wernsdörfer, Winfried Obhof, Uwe Meier, Arne Brosig, Rolf Malessa, Volker Limmroth, Gudrun Japp, Wolfgang Elias, Uwe K. Zettl, Norman Putzki
Publikováno v:
Journal of neurology. 254(1)
Interferon beta (IFN beta) preparations are the most frequently prescribed therapies for patients with relapsing multiple sclerosis (MS). Several open-label observational studies report similar efficacy among IFN beta preparations. The Quality Assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eb3723fb1d3125ce2d5b056ecf853c1
https://pubmed.ncbi.nlm.nih.gov/17273808
https://pubmed.ncbi.nlm.nih.gov/17273808
